Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques

Sponsor

SFA Therapeutics (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05642182

Collaborator

(none)

Enrollment

Locations

Arms

Anticipated Duration (Months)

Patients Per Site

0.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA004 on mild to moderate chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.

Condition or Disease	Intervention/Treatment	Phase
Psoriasis	Drug: Drug (SFA002) Vitamin D, Magnesium Drug: Drug (SFA002) Vitamin D, Magnesium and Propionate	Phase 1

Detailed Description

Up to sixty volunteers with mild to moderate chronic plaque psoriasis will be recruited for an open label 24 week prospective study of the safety of 2 different dosages for 12 weeks of active therapy and 12 weeks of follow up. Blood will be drawn to determine any clinical effect on each group at the 12 week time mark and residual effects after 24 weeks. Throughout the study the investigators will perform both clinical and laboratory assessments to measure safety and response.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Study of Improvement in Psoriasis Symptoms Associated With Combinations of Biologically Active Natural Substances (SFA-002) With Known Safety Profile

Actual Study Start Date :

Mar 31, 2022

Anticipated Primary Completion Date :

Mar 30, 2023

Anticipated Study Completion Date :

Jul 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Drug (SFA002) Vitamin D, Magnesium Drug (SFA002) 1000 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 IU once daily	Drug: Drug (SFA002) Vitamin D, Magnesium Capsules
Experimental: Drug (SFA002) Vitamin D, Magnesium and Propionate Drug (SFA002) 1000 mg, Propionate 150 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 mg once daily	Drug: Drug (SFA002) Vitamin D, Magnesium and Propionate Capsules

Arm

Intervention/Treatment

Experimental: Drug (SFA002) Vitamin D, Magnesium

Drug (SFA002) 1000 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 IU once daily

Drug: Drug (SFA002) Vitamin D, Magnesium

Capsules

Experimental: Drug (SFA002) Vitamin D, Magnesium and Propionate

Drug (SFA002) 1000 mg, Propionate 150 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 mg once daily

Drug: Drug (SFA002) Vitamin D, Magnesium and Propionate

Capsules

Outcome Measures

Primary Outcome Measures

Psoriasis Area and Severity Index (PASI) Score [Three months after study end]
+/- % Change in Psoriasis (PASI) index from baseline measurement at first dose

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects of both sexes ≥18 years of age with at least one skin plaque that is >5 cm2 due to known psoriasis considered clinically to be MILD to MODERATE during evaluation and diagnosis at least 1 year prior. Mild is defined as "Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling", whereas moderate is defined as "Clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling".
Have or have not been treated with phototherapy, systemic therapy, or other therapies for their psoriasis
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use effective contraceptive methods (such as abstinence, intrauterine device (IUD), or double barrier device) during the study and for at least 3 months following completion of the study.
Mentally competent, able to understand and willingness to sign the Informed Consent Form (ICF).
Able to undergo the investigations and to follow the visit schedule stated in the study protocol.

Exclusion Criteria:

The forms of psoriasis other than chronic plaque psoriasis (such as drug-induced psoriasis or guttate, erythrodermic, or pustular psoriasis) or if the psoriasis does not meet the criterion of chronicity (defined as a clinically significant flare of psoriasis within 12 weeks before baseline).
Presence of other form of inflammatory skin diseases (such as atopic dermatitis) or infectious diseases (such as cellulitis, warts, fungal cutaneous diseases, etc.)
A clinically significant flare of psoriasis within 12 weeks before baseline. (Note: The determination of whether prospective study participants had a "significant flare" prior to study baseline is left to the investigators. The intent of this criterion was to ensure the condition is sufficiently stable and aligned with the chronic nature of plaque psoriasis, so that an adequate assessment of the efficacy could be made.)
Prior or current use of psoriasis medications that might confound assessment of efficacy of the investigational supplements used in this study, unless there were used before their washout period prior to study initiation (see Table 2 for specific medications and their washout periods).
Known serious medical illness, such as significant cardiac disease (e.g., symptomatic congestive heart failure, unstable angina pectoris, symptomatic coronary artery disease, myocardial infarction within the past 6 months, uncontrolled or symptomatic cardiac arrhythmia, or New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase subjects' risk for toxicity.
Known to have a history of risk factors for torsade de pointes (e.g., clinically significant heart failure, hypokalemia, family history of Long QT Syndrome).
Known to have arterial thrombotic event, stroke, or transient ischemia attack within the past 12 months.
Known to have uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >90 mm Hg), or peripheral vascular disease ≥grade 2.
Known to have active central nervous system (CNS), epidural tumor or metastasis, or brain metastasis.
Any active uncontrolled bleeding, a bleeding diathesis (e.g., active peptic ulcer disease), or a history of bleeding (e.g., hemoptysis, upper or lower gastrointestinal [GI] bleeding) within the past 6 months.
Dyspnea with minimal to moderate exertion; large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); or any amount of clinically significant pericardial effusion.
Diabetes of any type, except Non-Insulin Dependent Diabetes Mellitus (NIDDM) that is controlled and with hemoglobin A1c 8%.
Evidence of active infection during screening, or serious infection within the past month.
Patients with known Human Immunodeficiency Virus (HIV), hepatitis B or C virus (HBV) or (HCV), respectively), or active or latent Tuberculosis (TB).
Serious or non-healing wound, skin ulcer, or bone fracture.
Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6 months.
Neuropathy of grade ≥2.
Pregnant or lactating females.
Patients like to purposely undergoing sunlight exposure, including the skin area where the plaques being investigated are located, during the study